APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease-Reference-Cited by-同舟云学术

APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease

Published:2024-01-16 Issue:5 Volume:134 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Datta Somenath,Antonio Brett M.,Zahler Nathan H.,Theile Jonathan W.,Krafte Doug,Zhang Hengtao^ORCID,Rosenberg Paul B.,Chaves Alec B.,Muoio Deborah M.^ORCID,Zhang Guofang,Silas Daniel,Li Guojie,Soldano Karen^ORCID,Nystrom Sarah^ORCID,Ferreira Davis,Miller Sara E.,Bain James R.^ORCID,Muehlbauer Michael J.,Ilkayeva Olga^ORCID,Becker Thomas C.,Hohmeier Hans-Ewald,Newgard Christopher B.^ORCID,Olabisi Opeyemi A.^ORCID

Funder

United States National Institute of Health

Publisher

American Society for Clinical Investigation

Link

https://www.jci.org/articles/view/172262/files/pdf

Reference68 articles.

1. Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans

2. APOL1 Kidney Disease Risk Variants: An Evolving Landscape

3. APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD

4. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene

5. APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Variant upon variant: kidney-disease risk associated with APOL1 G2 genetic variants is abrogated by the APOL1 p.N264K variant;Kidney International;2024-09

2. Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1–Mediated Kidney Disease (JUSTICE);Kidney International Reports;2024-09

3. Collapsing Glomerulopathy;Advances in Kidney Disease and Health;2024-07

4. The Two Levels of Podocyte Dysfunctions Induced by Apolipoprotein L1 Risk Variants;Kidney and Dialysis;2024-06-07

5. APOL1-Mediated Kidney Disease;JAMA;2024-05-21